Cover Image

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database

ObjectiveThe objective of this research is to scrutinize adverse events (AEs) linked to Trifluridine/Tipiracil (TFTD/TPI), using data from the FDA Adverse Event Reporting System (FAERS) database.MethodsThe AEs data related to TFTD/TPI were collected from the fourth quarter of 2015 through the fourth...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yongli Hu (Author), Yan Du (Author), Zhisheng Qiu (Author), Chenglou Zhu (Author), Junhong Wang (Author), Tong Liang (Author), Tianxiang Liu (Author), Mingxu Da (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
by: Daniel Sur, et al.
Published: (2022)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
by: Celia Lara-Morga, et al.
Published: (2023)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024)

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database
by: Xinnan Chen, et al.
Published: (2024)

New bioanalytical microemulsion Electrokinetic chromatography method for the simultaneous determination of Trifluridine with its metabolites and Tipiracil in rat plasma: Application to pharmacokinetic studies
by: Mohamed Hefnawy, et al.
Published: (2019)

Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
by: Wang X, et al.
Published: (2020)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
by: Yanjing Zhang, et al.
Published: (2024)

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database
by: Yunhe Fan, et al.
Published: (2024)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024)

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database
by: Qing Wan, et al.
Published: (2022)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
by: Xiaogan Wang, et al.
Published: (2024)

Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database
by: Ningsheng Tian, et al.
Published: (2024)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
by: Liyuan Liu
Published: (2024)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024)

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database
by: Feng Liu, et al.
Published: (2024)

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database
by: Chuanli Yang, et al.
Published: (2024)

Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database
by: Manxue Jiang, et al.
Published: (2024)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
by: Risako Hirai, et al.
Published: (2023)

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS
by: Yuan Peng, et al.
Published: (2024)

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
by: Shangze Li, et al.
Published: (2024)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)

Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database
by: Chengliang Wang, et al.
Published: (2024)

Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database
by: Zijian Guo, et al.
Published: (2024)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023)

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
by: Dan Liu, et al.
Published: (2024)

Drug-induced hearing disorders: a disproportionality analysis of the FAERS database
by: Baojian Li, et al.
Published: (2024)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024)

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database
by: Shi-Nan Wu, et al.
Published: (2024)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022)

A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases
by: Shupeng Zou, et al.
Published: (2024)

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
by: Dan Li, et al.
Published: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024)

Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
by: Zhiwen Fu, et al.
Published: (2024)

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
by: Khalidah A. Alenzi, et al.
Published: (2024)

Analysis of Factors Associated with Hiccups Using the FAERS Database
by: Ryuichiro Hosoya, et al.
Published: (2021)

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
by: PingPing Long, et al.
Published: (2024)

CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023)
by: Jing Shi, et al.
Published: (2024)